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Abstract 
BACKGROUND: Penile tumour is a rare tumour in the genitourinary system, account for 0.4-0.6%. Although rare, 
patients are often unaware and come in late stage, so the use of chemotherapy agents is becoming crucial.  
AIM: This study was conducted to evaluate responses and overall survival rate of Paclitaxel, Ifosfamide, and 
Cisplatin (TIP) regimen in penile cancer with nodal involvement. 
METHODS: We included all medical records of penile squamous cell carcinoma patients associated with nodal 
involvement who acquired TIP regimen in Adam Malik Hospital between 2014 and 2016. We administered 175 
mg/m
2
 of Paclitaxel on day 1, 1200 mg/m
2
 of Ifosfamide on days 1 to 3, and 25 mg/m
2 
of Cisplatin on days 1 to 3 
as our standard TIP regimen. The regimen was re-administered every 21-28 days. Characteristics of the patient 
including age, history of circumcision, races, primary lesion of the tumour and TNM staging were noted. Adverse 
event, clinical responses, and overall survival were assessed and evaluated. 
RESULTS: We extracted data from 17 patients of penile cancer with nodal involvement who acquired TIP 
regimen with a mean age of 44.18 ± 11.13 years old from our medical records. Only 10 patients completed the full 
4 cycles of the regimen. Four patients died before completion, two patients refused to continue the regimen, and 1 
patient is still on the second cycle. Total penectomy was the most frequent procedure had taken, and clinical 
stage T4 and N3 was the most findings at initial diagnosis. There was no complete response noted. Six patients 
were noted as partial response, and 1 patient was noted as progressive disease. The Kaplan-Meier curve shows 
an overall 6 months (95% CI: 4.4-7.6 months) of survival with a median of follow-up time was 7 (1-11) months. In 
subgroup analysis, we found that the responder group has significantly better overall survival than the non-
responder group (log-rank test, p = 0.004). 
CONCLUSION: Paclitaxel, Ifosfamide, and Cisplatin (TIP) regimen give significant clinical benefit in penile cancer 
with nodal involvement. 
 
 
 
 
 
 
 
 
Introduction 
 
The penile tumour is a rare tumour of the 
genitourinary system, found only 0.4-0.6 % from all 
incidence of malignancy among men in Europe and 
the United States of America. However, it made up 10 
% of all incidence of malignancy among men in Asian, 
South America, and Africa countries [1], [2]. In 
Indonesia, there is no clear data yet regarding the 
incidence of penile cancer. In eleven years (1994-
2005), there were 69 patients of penile cancer that 
recorded in Dr Cipto Mangunkusumo General Hospital 
and Dharmais National Cancer Center Hospital 
Jakarta [3]. In Sanglah Hospital Bali, there were 46 
patients of penile cancer during 8 years (1993-2001) 
[4]. Meanwhile, at Haji Adam Malik General Hospital 
Medan, the incidence of penile cancer during the last 
four years (2012-2015) was 34 patients [5]. 
Squamous cell carcinoma (SCC) of the penis was the 
most frequently found type of penile cancer [2], [5], 
[6].  
The principle of management for penile 
cancer is to remove the tumour with as much organ 
preserved as possible, by either partial or total 
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penectomy, as an effort to reduce recurrence. Aside 
from treating the primary tumour, the involvement of 
lymph nodes is also an important factor to improve the 
patient’s prognosis. Penile cancer is an aggressive 
disease, and the success of local lesion treatment is 
only when it is treated during the early stages. 
Meanwhile, penile cancer in late stages, accompanied 
by the involvement of regional lymph nodes or distant 
metastases, is still considered as a challenging 
problem for euro-oncologists [7].  
Patients with unilateral lymph nodes 
metastasis, without extranodal involvement or 
involvement of pelvic lymph nodes, had a low 
recurrence rate of 10% to 20% after surgical 
management only. The recurrence rate was higher in 
patients with metastasis of bilateral lymph nodes, 
extranodal involvement, or the involvement of pelvic 
lymph nodes; which was 80% to 90% [8], [9]. The 
multi-modality approach, an approach combining 
chemotherapy and aggressive surgical management, 
might be effective, even though the local recurrence 
rate and progressivity were still high. Zou et al. 
reported that the administration of chemotherapy 
before lymphadenectomy on penile cancer patients 
with the involvement of regional lymph nodes (N3) 
showed great benefits. The administration of 
combination chemotherapy of bleomycin, methoprene, 
and cisplatin before lymphadenectomy resulted in 5-
year overall survival rate 45.8%. This result 
statistically was greater in patients who were 
responsive to chemotherapy compared to those who 
were unresponsive (73.3% vs 0%, p < 0.001) [10]. 
Sarma et al. provided chemotherapy as adjuvant 
chemotherapy for patients with penile cancer after the 
removal of pelvic lymph nodes. The research showed 
an improvement in overall survival [11]. In cases 
where there were systemic metastases, 
chemotherapy was the choice of treatment [7], [12].
 
 
Various chemotherapy regiments were used 
as part of the management for penile cancer, either as 
neoadjuvant or adjuvant therapy. Cisplatin, bleomycin, 
and methotrexate were first used as single anti-
tumour agents for penile cancer in the year 1975. 
However, the response rate was still low, with severe 
adverse effects; especially for bleomycin which was 
toxic for lungs [13].
  
Therefore, to improve the response rate of 
chemotherapy in penile SCC, various combinations of 
chemotherapy regimens were tested, the 
combinations usually consisted of two to three drugs 
[14]. The use of combined chemotherapy regiments 
was first reported by Shmmas et al., using 1000 
mg/m
2 
5-fluorouracil (5-FU) and 100 mg/m
2 
cisplatin 
with three weeks intervals. Results from the research 
showed partial responses in two out of a total of eight 
cases treated, with adverse effects including 
septicemia, decreased renal function, nausea, and 
vomiting [15].  
Regiment of taxane-based chemotherapy has 
been successfully used to treat SCC from two 
different locations. Combination chemotherapy using 
paclitaxel has been used to treat penile SCC since 
early 2000. Bermejo et al., used a combination of 
paclitaxel as neoadjuvant chemotherapy on two 
patients, resulting in prolonged post-chemotherapy 
survival rate followed by the removal of lymph nodes 
[16].  
Joerger et al. reported significant remission in 
one of the patients with advanced disease after three 
cycles of paclitaxel/carboplatin [17]. The two types of 
research reported that the regiments were well 
tolerated [16], [17]. Pagliaro et al. conducted a phase 
two clinical trial of taxane-based chemotherapy 
regiment as neoadjuvant chemotherapy for penile 
SCC with the involvement of lymph nodes; the results 
showed that taxane-based chemotherapy had good 
response towards penile cancer with metastases to 
lymph nodes [12].  
Reports regarding the use of taxane-based 
regiment for the management of penile SCC, either as 
neoadjuvant or adjuvant chemotherapy, were still 
limited so far. This condition might be due to the small 
number of penile SCC cases. At Haji Adam Malik 
General Hospital, the use of taxane as part of the 
chemotherapy regimen for penile SCC has been 
started since 2014. This study aims to evaluate the 
response for the administration of chemotherapy 
paclitaxel, ifosfamide, and cisplatin (TIP) regiments as 
well as to evaluate the overall survival (OS) rate. 
 
 
Methods 
 
This research is a retrospective, descriptive 
analytic study. Samples were collected from the year 
2014 to 2016. Samples were patients with penile SCC 
which has been confirmed with histopathological 
examination results: enlargement of either unilateral 
or bilateral lymph nodes > 4 cm, with no signs of 
distant metastases. Patients with enlargement of 
pelvic lymph nodes found through computed 
tomography (CT) scan imaging were also included in 
the study, with or without biopsy results.  
We used chemotherapy regimen TIP 
consisting of four cycles of paclitaxel 175 mg/m
2
 on 
day 1, ifosfamide 1200 mg/m
2
 on day 1 to 3, and 
cisplatin 25 mg/m
2
 on day 1 to 3 with duration of 21-28 
days. Patient’s characteristics including age, ethnic, 
primary lesion, and TNM staging were noted. 
Occurring adverse effects, clinical response rate post-
chemotherapy based on Response Evaluation Criteria 
in Solid Tumors (RECIST) criteria [18] and overall 
survival rate were also noted. 
 
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1150                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
Results 
 
There were 17 patients of penile cancer with 
the involvement of lymph node, who received 
chemotherapy regiment consisting of paclitaxel, 
ifosfamide, and cisplatin from June 2014 to December 
2016 at Haji Adam Malik General Hospital Medan. Out 
of a total of 17 patients, only 10 patients who 
managed to receive the full regimen of chemotherapy 
completely. Meanwhile, four patients passed away 
before completing chemotherapy, two patients refused 
to continue receiving chemotherapy, and one patient 
was still on the second cycle of chemotherapy in 
December 2016. Patients’ characteristics were shown 
in table 1.  
In this research, we found that the mean age 
of patients was 44.18 ± 11.13 years old. All samples 
were Bataknese, and 16 patients (94.1%) were 
uncircumcised. Primary tumour lesion was found on 
the penile shaft (58.8%) and penile base (35.3%), with 
pathological results showing that 35.3% tumour had 
invaded surrounding tissues (T4) and had fixated 
nodules (N3) in 10 patients (58.8%). There was no 
patient found with distant metastases when 
diagnosed. Three patients had tumour staging Tx 
because they underwent an operation at other 
hospitals and their histopathological assessment 
results did not describe the T staging of their tumour. 
Table 1: Baseline characteristics of patients (N = 17) 
Characteristics  Number of 
patients 
 Percentage 
Age (year)     
 Mean 
Circumcision 
 Yes 
 No 
  
 
1 
16 
44.18 ±11.13  
 
5.9 
94.1 
Ethnic     
 Batak  17  100 
Location of the 
primary tumour 
    
 Penile glans 
 Penile shaft 
 Penile base 
 1 
10 
6 
 5.9 
58.8 
35.3 
Tumour Staging  
 T1a 
 T1b 
 T2 
 T3 
 T4 
 Tx 
  
0 
1 
3 
3 
7 
3 
  
0 
5.9 
5.9 
17.6 
35.3 
35.3 
Nodule Staging  
 N0 
 N1 
 N2 
 N3 
  
0 
3 
4 
10 
  
0 
17.6 
23.5 
58.8 
Metastasis   0  0 
Type of operation 
 Partial penectomy 
 Total penectomy 
  
6 
11 
  
35.3 
64.7 
Histopathological type 
 SCC 
  
17 
  
100 
 
Eleven patients (64.7%) who received 
chemotherapy with paclitaxel, ifosfamide, and cisplatin 
underwent total penectomy while 6 patients (35.3%) 
underwent partial penectomy; the histopathological 
type of all tumour (100%) was squamous cell 
carcinoma (SCC).  
 
Table 2: Response to chemotherapy after four cycles of TIP 
Response towards 
chemotherapy 
Frequency Percentage 
Complete response 0 0 
Partial response 6 60 
Stable 3 30 
Progressive 1 10 
 
There was no patient with a complete 
response. However, there were six patients with 
partial responses, three patients with a stable 
response, and one patient showed progressive 
disease. 
Table 3: Adverse effects during chemotherapy of TIP  
Adverse effects Frequency (n)  
 
Percentage (%) 
Neutropenia 8  47.1 
Thrombocytopenia 7  41.2 
Anaemia 14  82.4 
Mucositis 6  35.3 
Nausea 12  70.6 
Diarrhoea 2  11.8 
Constipation 0  0 
Alopecia 15  88.2 
Allergy 0  0 
 
Eleven out of 17 patients receiving 
chemotherapy passed away with median overall 
survival (OS) of 6 months (95% CI: 4.4-7.6 months). 
The median time for follow up was seven months 
(ranging from 1 to 11 months). 
 
Figure 1: Kaplan-Meier graph overall survival rate (OS)  
 
We conducted subanalysis towards the 
responsive and unresponsive sub-groups regarding 
the administration of paclitaxel, ifosfamide, and 
cisplatin-based chemotherapy. Eight patients passed 
away in the unresponsive group, while only two 
patients passed away in the responsive group. The 
overall survival rate was significantly higher in 
responsive patients compared to unresponsive 
patients (log-rank test, p ꞊ 0.004). 
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Figure 2: Kaplan-Meier graph overall survival rate (OS) of 
responsive and unresponsive sub-groups 
 
 
 
Discussion 
 
Based on our experiences in using paclitaxel, 
ifosfamide, and cisplatin-based chemotherapy as part 
of penile cancer management in Haji Adam Malik 
General Hospital, Medan, we found 17 patients who 
received the regiment from June 2014 to December 
2016. Penile cancer is an aggressive disease, in 
which success for local lesion management could only 
be achieved during the early stages. The success of 
penile cancer management with regional and systemic 
metastases is still a challenge for urologists. In 
situations where there were metastases on regional 
lymph nodes, administration of chemotherapy 
combined with aggressive surgical management might 
be effective, even though the recurrence rate and 
progressivity were still high. In cases where systemic 
metastasis was found, chemotherapy becomes the 
only choice of treatment [7].  
Most penile cancers are squamous cell 
carcinoma (SCC). In this research, the 
histopathological type of all samples was SCC (100%) 
with T4 (35.3%) and N3 (58.8%) as the most common 
staging results. Thus, it can be concluded that most 
patients who came to Haji Adam Malik General 
Hospital Medan were already in the late stages of the 
disease. This condition is commonly found in patients 
with penile SCC, as also found in the research by 
Lynch and Krush, which reported 15-50% patients 
delayed up to one year before they are finally looking 
for treatment [19].  
There were six patients with partial responses 
after four cycles of chemotherapy in our research; 
however, there was no sample which showed a 
complete response. In the research by Pagliaro, there 
were found three patients with complete response and 
twelve patients showing the partial response from total 
research samples of 30 patients; 13.6% of all patients 
showing a complete pathological response (pCRs) 
[12]. Other researches which used a taxane-based 
combination as neoadjuvant chemotherapy in 
advance stage penile cancer resulted in 60% 
responsive patients, with 4% showing complete 
pathological response [20]. Kubota et al. reported that 
the TIP combination was effective for penile cancers 
with the involvement of lymph nodes [21].  
The administration of chemotherapy for penile 
cancer with lymph nodes metastases is quite 
common. Both adjuvant and neoadjuvant 
chemotherapy could increase overall survival [12], 
[16], [22], [23]. The largest prospective research by 
the Southwest Oncology Group (SWOG) reported of 
patients receiving a combination of bleomycin, 
methotrexate, and cisplatin. In the research, the 
overall survival rate was 32.5% with median overall 
survival of 28 weeks. Even though the overall survival 
rate for the regimen was quite high, it was not well 
tolerated since there was also a high mortality rate 
due to chemotherapy (13.9%) [23]. Our study showed 
an overall survival of 6 months. This result was lower 
when compared to the results from the study by 
Pagliaro, which was OS 17.1 months [12]. This 
difference might be caused by the fact that in this 
research, the intervention was only chemotherapy; 
there was no patient who underwent inguinal 
lymphadenectomy (ILND). 
Sub-group analysis of patients who were 
responsive and unresponsive to chemotherapy 
showed a statistically significantly higher overall 
survival in patients who were responsive to 
chemotherapy (11 months vs 2 months, p ꞊ 0.004). 
The response towards chemotherapy might be used 
as predictors for chemotherapy success as part of 
management for penile cancer.  
There were a few adverse effects occurring 
during the administration of TIP. In this study, the 
most commonly found adverse effects included 
alopecia, nausea, and anaemia. The alopecia was 
temporary and will subside once the chemotherapy 
was stopped. Djajadiningrat et al. discovered a few 
adverse effects during the administration of taxane-
based combination chemotherapy in each patient and 
concluded that the adverse effects of taxane-based 
combination chemotherapy were less well-tolerated 
[20].
 
 
In conclusion, the administration of paclitaxel, 
ifosfamide, and cisplatin-based chemotherapy is 
effective, showing improvement in overall survival of 
patients with penile cancer, with the involvement of 
regional lymph nodes. Patients who were responsive 
to chemotherapy had longer overall survival, although, 
a combination of chemotherapy and surgical 
management will show better results. 
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